Intrauterine Blood Transfusion: Current Indications and Associated Risks

Irene T.M. Lindenburg  Inge L. van Kamp  Dick Oepkes
Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands

Abstract
Fetal anemia is a serious complication in pregnancy and associated with perinatal mortality and morbidity. During 25 years of worldwide experience with intravascular intrauterine blood transfusion, a variety of indications have been described. Intravascular transfusion (IUT) treatment is considered most successful for fetal anemia due to red cell alloimmunization. Moreover, the use of this procedure has also been reported in pregnancies with parvovirus B19 infection, fetomaternal hemorrhage and placental chorionangiomas, for example. This review focuses on the current indications of intravascular blood transfusions. In addition, we describe the potential complications of IUT treatment.

Introduction
In the early 1960s, intravascular treatment of fetal anemia due to red cell immunization by percutaneous intraperitoneal transfusion was introduced by Liley. Initially, Liley [1] devised bilirubin extinction in amniotic fluid as a diagnostic tool for fetal alloimmune anemia [2]. At one occasion, erroneously he collected ascites instead of amniotic fluid and this event brought him the idea that intraperitoneal blood transfusion could be an effective method to correct fetal anemia. Fetal position was determined by X-ray to visualize the persistence of swallowed water-soluble contrast medium ‘urografin’ in the fetal gut, which was combined with fat-soluble contrast medium to visualize the outline of the skin. Under local anesthesia, a needle was inserted into the fetal peritoneum. Although survival rates improved, outcome, especially of hydropic and very young anemic fetuses, remained poor.

The currently used technique, intravascular intravascular intraperitoneal transfusion (IUT) into the umbilical cord, was first described by Rodeck et al. [3] in 1981 using guidance of the needle by fetoscopy. Advances in the resolution of ultrasound enabled pioneers such as Ferdinand Daffos in Paris and Jens Bang in Copenhagen to perform ultra-
sound-guided cordocentesis and blood transfusion directly into the umbilical vein [4, 5]. IUT into the intrahepatic portion of the umbilical vein was first described by Nicolini et al. [6] in 1990, and it can be a safe alternative for umbilical cord transfusion in particular in case of a posterior placenta [7]. In the Netherlands, IUT was introduced in 1965 by Bennebroek Gravenhorst et al. [8]. From 1987 onwards, the intravascular technique became the method of choice [9]. Consequently, IUT continues to be the cornerstone of treatment for fetal anemia for a variety of causes. In experienced hands, IUT is now considered a relatively safe procedure. However, complications, even fatal ones, do still occur. This review summarizes the current indications and associated risks of the most successful invasive treatment in fetal medicine.

Data Sources

The MEDLINE database (http://www.ncbi.nlm.nih.gov/pubmed/) and the Cochrane Library (http://www.cochrane.org/) were used to conduct a literature search to identify relevant articles up until December 2013. The search was restricted to articles published in English. Priority was given to articles reporting results of original research, although review articles and case reports were also included.

Indications for IUT

Fetal anemia results from the degradation or hemolysis of normal red cells, (temporarily) impaired red cell production, loss or dilution, hemoglobinopathies and erythrocyte membrane or enzymatic disorders. In any fetal disease with severe anemia, intrauterine blood transfusion may be considered. However, as in all invasive procedures in fetal therapy, knowledge of the indication and the underlying disease is important for a successful outcome. The main indication for intrauterine blood transfusion is still fetal anemia due to red cell alloimmunization. Fetal erythrocyte treatment has also been reported to be successful in nonimmune etiology, such as human parvovirus B19 infection, fetomaternal hemorrhage (FMH), twin-twin transfusion syndrome, placental/fetal tumors and other rare diseases (table 1).

The assessment of bilirubin in amniotic fluid was initiated by Liley [2] in 1961 and used to be standard management of red cell alloimmunization in pregnancy. Today, this invasive method has been replaced by serial Doppler determinations of the middle cerebral artery peak systolic velocity (MCA-PSV) in the detection of fetal anemia [10, 11]. MCA-PSV can be initiated already at 16–18 weeks of gestation. Reliability decreases after 35 weeks of gestation [12]. MCA-PSV has been found to be also useful in identifying fetal anemia in cases of nonimmune hydrodrops, FMH, chorioangioma, α-thalassemia and monoclonic (MC) twins [13].

Most centers perform fetal transfusions up to 35 weeks of gestation, with delivery anticipated at 37–38 weeks. IUT treatment after 32 weeks of gestation may be safer than procedures performed in early gestation and may prolong pregnancy until safe term and improve outcome [14]. However, every IUT carries a risk of procedure-related asphyxia, especially in a compromised fetus. These aspects should be contemplated when considering IUT in advanced gestation, including the assumed risks of an elective delivery.

Red Cell Alloimmunization

Hemolytic disease of the fetus and newborn (HDFN) results from maternal alloimmunization to red cell antigens, for which mother and fetus are incompatible. Maternal red cell IgG antibodies pass the placenta into the fetal circulation and may cause hemolysis. More than 50 red cell antigens have been associated with HDFN. The most prevalent red cell antibodies are RhD, Kell and Rhc. Other antibodies associated with severe HDFN are anti-Rh-e/E (Rhesus), Fy(a)/Fy(b) (Duffy blood group), Kidd (Jka) and anti-M (MNS system) [15, 16]. In the Netherlands, the prevalence of severe HDFN due to maternal alloimmunization to antibodies is 0.05% (100/200,000 live-born infants per year).

In the past decade, survival rates after IUT for red cell alloimmunization exceeded 80% in specialized centers all over the world (table 1). One long-term concern of IUT is that advances in treatment techniques have allowed more hydroptic fetuses to survive, and these infants may be at higher risk of long-term morbidity. In a few small studies, the incidence of severe adverse long-term outcome ranges from 2.8 to 13% [17–19]. Recently, a larger follow-up study (LOTUS study) analyzed outcome after a total of 1,284 IUTs performed in 451 fetuses in a 20-year period [20]. Alloimmunization was due to RhD in 80%, Kell in 12% and Rhc in 5% of the cases. Twenty-six percent of the fetuses were hydroptic at the first transfusion and the mean gestational age at first transfusion was 26 weeks; the mean number of transfusion was 3. The vast majority (>95%) of children had a normal neurodevelopmental outcome. The major preoperative risk factor for neurodevelopmental
impairment was the presence of hydrops. Prevention of fetal hydrops by timely detection and treatment may improve long-term outcome. The high rate of intact survival confirms the success of IUT for alloimmune anemia.

Intraperitoneal transfusion was first reported by Liley [1] in 1963 and relies on injecting red cells into the peritoneal cavity. These cells are transported through the lymphatic system to the fetal circulation. This absorption may be impeded in case of severe hydrops. A combined intravascular and intraperitoneal approach may allow longer intervals between procedures [21]. Intraperitoneal transfusion may still be a reasonable alternative if attempts to perform intravascular transfusion fail, or in addition to IUT performed in the intrahepatic part of the umbilical vein. Alternatively, in very severely affected pregnancies, with early loss, hydrops or a first IUT <24 weeks of gestation in the previous pregnancy, frequent monitoring can be combined with maternal intravenous immunoglobulin (IVIG) administration and/or plasmapheresis in an effort to delay the first IUT and thus reducing the risk for procedural complications [22, 23].

A case study reported on 6 women [22] who in previous pregnancies had evidence of severe anemia before 20 weeks of gestation with mortality in 4 of the 6 previous pregnancies. All women received prophylactically serial IUTs between 16 and 21 weeks of gestation combined with maternal IVIG in 4/6 cases. Six of the 7 fetuses (1 twin) survived, suggesting an advantage of this approach.

### Table 1. Survival rates per indication for intrauterine blood transfusion

<table>
<thead>
<tr>
<th>Indication</th>
<th>n</th>
<th>Survival</th>
<th>First author, year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red cell alloimmunization</td>
<td>30–491</td>
<td>80.5–93.5%</td>
<td>van Kamp [7], 2005; Yinon [50], 2010; Tiblad [51], 2011; Johnstone-Ayliffe [52], 2012; Osanan [53], 2012; Lindenburg [54], 2013</td>
</tr>
<tr>
<td>Parvovirus B19 infection</td>
<td>16–73</td>
<td>66.7–72.7%</td>
<td>Nagel [29] 2007; Enders [24], 2004; de Jong [28], 2013</td>
</tr>
<tr>
<td>FMH</td>
<td>4</td>
<td>4/4</td>
<td>Thorp [66], 1992; Montgomery [67], 1995; Rubod [68], 2006; Votino [69], 2008</td>
</tr>
<tr>
<td>Twin-twin transfusion syndrome</td>
<td>4–13</td>
<td>75–76.9%</td>
<td>Robyr [35], 2006; Lopriore [37], 2009</td>
</tr>
<tr>
<td>Chorioangioma</td>
<td>6</td>
<td>2/6</td>
<td>Haak [70], 1999; Horigome [71], 1997 (died); Hirata [72], 1993; Escribano [73], 2006; Bermúdez [74], 2007 (died); Ercan [75], 2012</td>
</tr>
<tr>
<td>Fetal sacrococcygeal teratoma</td>
<td>3</td>
<td>2 NR, 1 died</td>
<td>Wee [41], 2011; Amann [42], 2011 (NR)</td>
</tr>
<tr>
<td>Kaposi-like hemangioendothelioma</td>
<td>1</td>
<td>1</td>
<td>Amann [42], 2011</td>
</tr>
<tr>
<td>Homozygous α-thalassemia</td>
<td>5</td>
<td>5/5</td>
<td>Carr [46], 1995; Ng [47], 1998; Wang [48], 2009; Leung [49], 2002</td>
</tr>
<tr>
<td>β-Thalassemia</td>
<td>1</td>
<td>1</td>
<td>Brantberg [76], 2009</td>
</tr>
<tr>
<td>Xerocytosis</td>
<td>2</td>
<td>2</td>
<td>Ogburn [77], 2001; Sánchez [78], 2005</td>
</tr>
<tr>
<td>Elliptocytosis</td>
<td>1</td>
<td>1</td>
<td>Amann [42], 2011</td>
</tr>
<tr>
<td>Blackfan-Diamond anemia</td>
<td>3</td>
<td>2/3</td>
<td>Amann [42], 2011; van Hook [79], 1995 (died); McLennan [80], 1996</td>
</tr>
<tr>
<td>Congenital dyserythropoietic anemia</td>
<td>1</td>
<td>1</td>
<td>Remacha [81], 2002</td>
</tr>
<tr>
<td>Hemochromatosis</td>
<td>1</td>
<td>0</td>
<td>Amann [42], 2011</td>
</tr>
<tr>
<td>Mucopolysaccharidosis VII</td>
<td>1</td>
<td>1</td>
<td>Amann [42], 2011</td>
</tr>
<tr>
<td>Cytomegalovirus infection</td>
<td>1</td>
<td>NR</td>
<td>Amann [42], 2011</td>
</tr>
<tr>
<td>Congenital syphilis</td>
<td>1</td>
<td>1</td>
<td>Chen [82], 2010</td>
</tr>
</tbody>
</table>

NR = Not reported.
In a series of 9 with a history of fetal hydrops, anemia or fetal demise before 24 weeks of gestation in previous pregnancies, combined therapy with plasmapheresis and IVIG for the treatment of alloimmunization in pregnancy has been applied [23]. Four of the 9 pregnancies had Kell immunization. Plasmapheresis was given every other day, starting after the 12th week of gestation. After the 3rd plasmapheresis, IVIG was administered. All infants survived, and maternal antibody titers were significantly reduced after plasmapheresis and remained decreased during IVIG therapy. The optimal treatment modality for early-onset severe red cell immunization is not known and provides a challenge for further studies.

**Parvovirus B19 Infection**

Human parvovirus B19 is a potent inhibitor of hematopoiesis and may cause bone marrow failure via the involvement of erythroid lineage cells. In 30–50% of pregnancies infected with parvovirus B19, vertical transmission takes place and leads in 1–2% to infection of the fetus, which may cause serious fetal morbidity and mortality. A fetus affected by parvovirus B19 may show signs of anemia on ultrasound investigation, such as (severe) hydrops, a hyperdynamic circulation and cardiomegaly. Although spontaneous resolution of fetal anemia due to parvovirus has been described, timely IUT can correct fetal anemia and reduces mortality [24]. In most cases, a single transfusion will lead to recovery. The presence of thrombocytopenia is frequently encountered in fetal parvovirus B19 infection and intrauterine platelet transfusion can be performed relatively safely, although the risk of fluid overload in the hydropic fetus should be weighed against the low incidence of fetal bleeding complications [25]. Perinatal survival after treatment with IUT for fetal anemia due to parvovirus ranges from 67 to 73% (table 1). Nevertheless, there is a risk for neurological damage, especially in hydropic fetuses, which comprise the majority of cases. This leads to the obvious suggestion that IUT should preferably be done before hydrops develops. In the absence of screening programs for parvovirus susceptibility or infection in pregnant women, the majority is still referred only after the detection of hydrops [26–29].

**Fetomaternal Hemorrhage**

FMH is defined as the passage of fetal blood into the maternal circulation and is a serious rare complication in pregnancy. Massive FMH will lead to severe fetal anemia. Other fetal problems include distress, hydrops, hypovolemic shock and death. These pregnancies often present clinically because of decreased or absent fetal movements. A Kleihauer test to estimate the volume of hemorrhage and Doppler evaluation of fetal flow velocities (MCA-PSV) to detect fetal anemia may aid in disease management [30]. IUT corrects fetal anemia and can prolong gestation until a more mature gestational age is reached. Perinatal death varies between 31 and 50% [30–32]. The outcome of long-term survivors after severe anemia due to FMH is not well known but includes neurological sequelae [31, 32]. de Almeida and Bowman [31] reported the neurological outcome of 15 FMH patients. One infant was diagnosed with cerebral palsy at 6 years of age. Kecskes [32] evaluated the short-term neurological outcome of 16 neonates with demonstrated FMH >20 ml. Five (31%) had an adverse outcome: death in 3 patients and periventricular leukomalacia in 2 patients. Adverse outcome was better predicted by hemoglobin at birth than by estimated volume of hemorrhage calculated by the Kleihauer test. Whether outcome could be improved by IUT treatment is not known because of the rarity of this disease and the lack of follow-up studies.

**Twin-Twin Transfusion Syndrome**

Fetofetal transfusion due to communicating vascular anastomoses in MC twin pregnancies may result in fetal anemia of the donor twin and polycythemia in the recipient: twin anemia polycythemia sequence (TAPS) [33]. TAPS occurs spontaneously in 3–5% of MC twin pregnancies and in up to 13% of twin-twin transfusion syndrome cases treated with laser surgery. There are several management options for TAPS, including IUT, (repeat) laser surgery, elective delivery and expectant management. Treatment with IUT may help to correct the donor twin’s anemia, but may potentially deteriorate the plethoric twin’s condition [34, 35]. Therefore, a combination of IUT to the donor with an exchange transfusion in the recipient twin can be considered [36, 37]. Herway et al. [38] performed intraperitoneal IUT with the idea that this technique would not increase the fetal blood pressure and would allow the slow absorption of red blood cells. The best management of TAPS has yet to be determined.

Cerebral injury in TAPS cases treated with or without IUT may be less uncommon than initially thought [39]. Follow-up data on the long-term neurodevelopmental outcome in TAPS are lacking. More studies are necessary to determine whether IUT is a successful option in the management of TAPS.

**Placental and Fetal Tumors**

Placental chorioangioma is a vascular tumor of the placenta and occurs in approximately 1% of pregnancies.
Most tumors are small and asymptomatic. Large chorioangiomas are clinically significant and may cause serious complications, such as fetal anemia, hydrops and fetal death. Fetal anemia may be a result of FMH (shunting of large volumes of blood to the tumor) and/or hemolysis because of the entrapment and destruction of fetal erythrocytes in the vascular network of the chorioangioma. In the literature, 7 cases of fetal anemia associated with placental chorioangioma treated with IUT have been described (Table 1). Treatment with IUT may improve fetal condition and may prevent preterm delivery. Alternative treatment options are (serial) amnioreduction, intratumoral injection of alcohol or pharmacotherapy and fetoscopic devascularization [40].

Fetal sacrococcygeal teratoma may lead to anemia due either to hemorrhage or hemolysis within the tumor and is associated with poor survival. Three cases with fetal anemia associated with sacrococcygeal teratoma treated with IUT have been described (Table 1). Wee et al. [41] presented a fetus with sacrococcygeal teratoma complicated by anemia that received 3 IUTs. Unfortunately, the neonate died shortly after birth. The outcome of the other 2 cases is not reported [42]. Other known fetal interventions are cyst aspiration, amnioreduction, amnioinfusion, open fetal surgical resection [43], radiofrequency ablation or tumor or abdomino-amniotic shunt [44].

Iacovella et al. [45] described the long-term neurodevelopmental outcome of a small cohort of placental and fetal tumors in pregnancy determined by interviews (28 chorioangiomas and 10 sacrococcygeal teratomas). The 5 infants with neurodevelopmental delay were all cases of chorioangioma. Abnormal developmental delay may be associated with fetal high-output cardiac failure.

**Rare Causes of Fetal Anemia**

Rarely, IUT has also been used to treat severe fetal anemia due to α-thalassemia [46–48]. A fetus with homozygous α-thalassemia has a gene defect and cannot produce normal fetal hemoglobin but produces Hb Bart. Bart’s fetal hydrops is usually incompatible with extrauterine life. However, antenatal diagnosis and IUT treatment has resulted in some surviving patients, but long-term survival depends on neonatal red cell transfusions and subsequent bone marrow transplantation [48, 49].

Other rare causes of fetal anemia treated with IUT have been described (Table 1). However, (long-term) outcome data have not always been reported. It is still unknown whether IUT has to be considered in these cases; maybe, successful cases are overrepresented in the literature.

**Associated Risks of IUT**

Nowadays, IUT is considered a safe method to correct severe fetal anemia. However, procedural complications sometimes occur and may affect outcome.

**Acute Procedure-Related Complications**

Fetal distress during or after the procedure is the most serious complication and may result in fetal death or emergency delivery with the risk of prematurity, neonatal asphyxia or death. Fetal distress can occur after local cord accidents (rupture, spasm, tamponade from a hematoma or excessive bleeding), volume overload, chorioamnionitis, preterm rupture of membranes or preterm labor [7, 50–54].

Fetal demise after intrauterine treatment may be the result of an already compromised fetal state or due to the invasive procedure itself. In the literature, procedure-related fetal loss ranges from 0.9 to 4.9% per procedure [7, 50–54] and was found to be associated with fetal hydrops [54, 55], early gestational age [50, 51], failing to use fetal paralysis during IUT [7], transfusion at a free loop of cord or arterial puncture [7, 52], experience of the operator [52, 56] and severity of fetal anemia [53]. Interestingly, preterm premature rupture of membranes after transfusion appears extremely rare, e.g. 0% [52], 0.1% (1/740) [7], 1.3% (4/305) [53], 0.4% (1/284) [51] and 0.2% (1/631) [50] of cases in the largest series. The incidence rates of chorioamnionitis reported in the literature are 0% [51], 0.3% (2/740) [7] and 1.0% (3/305) [53]. In both cases described by van Kamp et al. [7] in 2005, the bacterium *Escherichia coli* caused the intrauterine infection. From the low incidence of infection after IUT, routine use of antibiotic prophylaxis at IUT is not advised.

**Long-Term Complications**

Neonates treated with IUT require more top-up red blood cell transfusions during the first 6 months of life, which may be explained by the suppression of fetal erythropoiesis [57, 58]. Red blood cell donor transfusions have a minimal but theoretical risk for anaphylactic reactions and transmission of viral diseases.

IUT, transplacental puncture in particular, is also associated with the formation of new red cell antibodies [59]. Additional antibodies are formed by small FMH after IUT. The prevalence of additional maternal red cell antibodies is 19–26% and may complicate present and subsequent pregnancies and future transfusions [59, 60]. The presence of additional antibodies causes problems in...
selecting compatible red blood cells for fetal and maternal transfusions, and the antibodies are capable of inducing delayed hemolytic transfusion reactions.

Improving Outcome

With the use of high-resolution ultrasound to guide invasive obstetric procedures, IUT rapidly became safer. Ultrasonography during IUT is essential for guiding the procedure as well as monitoring of the fetal condition. Fetal distress secondary to local cord accidents may be a result of sudden fetal movements and dislodgment of the needle from its intended site. The use of fetal paralysis may prevent procedure-related fetal loss in 80% of the cases and thus improve the safety of the procedure [7, 61]. Even more, prevention of volume overload by adjusting transfusion speed to gestational age, especially in young fetuses and/or hydropic fetuses, may improve outcome [25, 62].

Fetal distress may also be associated with (inadvertently) puncturing an artery, causing spasm of the vessel or excessive bleeding at the site of the injection [7]. Although the various points of access to the fetal circulation in relation to fetal loss have not been compared in randomized trials, arterial puncture should therefore be avoided.

The presence of hydrops due to severe anemia is the main prognostic factor affecting survival after IUT therapy [54, 55, 63]. In addition, (alloimmune) fetal hydrops is a major risk factor for long-term neurodevelopmental impairment [20]. Early and timely detection, referral and treatment may prevent hydrops and improve (long-term) outcome. For red cell alloimmunization, universal screening programs have been implemented in most Western countries and aimed at early detection. For fetal infections causing anemia, such as parvovirus B19, no screening programs exist, which means that family doctors, midwives and obstetricians have the responsibility to have a high index of suspicion for this infection in pregnancy and test any pregnant woman with a likely contact with an infected individual.

Avoiding transplacental transfusion, carefully matching the IUT donors for immunogenic antigens, and possibly the use of a single donor serially donating small volumes for 1 particular anemic fetus may prevent the induction of additional antibodies during IUT treatment for alloimmune anemia [58]. However, the mechanism of this immunization phenomenon in pregnant women is still not fully understood [63]. It has been postulated that a high antibody titer during pregnancy together with new antibody formation after IUT were associated with a higher human leukocyte antigen immunization rate or so-called ‘high respondership’ [64]. The clinical relevance and consequences of leukocyte antibodies are not very clear as both harmful and beneficial effects have been described [65].

Conclusion

IUT can nowadays be considered a safe and successful method to treat severe fetal anemia for different indications. The two most common indications for intrauterine blood transfusion are fetal anemia due to red cell immunization and parvovirus B19 infection in pregnancy. When considering IUT for fetal anemia due to other (rare) diseases, a careful individual risk-benefit analysis must be made each time. Concerning alternative therapeutic options, no conclusive proof of benefit can be demonstrated. In this respect, centralization of knowledge and skills is of great importance in order to create an optimal management of fetal anemia detected in pregnancy. This indicates the need for an international register to document management, complications and (long-term) outcome of cases.

Disclosure Statement

We declare no conflicts of interest.

References

Intrauterine Blood Transfusion


